Last 12 months
Inside the activity.
2 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 1 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 29, 2026 Filed Mar 31, 2026 16:16 UTC |
Stahler Rachel AChief Information Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 8,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022424 · wk-form4_1774988203.xml · derivative · entry 3 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,201 Underlying: Common Stock · 8,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F3 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. F3 · derivative.expiration_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 16:16 UTC |
Stahler Rachel AChief Information Officer
|
Tax withholdingCommon Stock | 2,809 | $5.84 | $16,404.56 |
DisclosureSEC source: 0001628280-26-022424 · wk-form4_1774988203.xml · nonDerivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,701.292 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 27, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 16:16 UTC |
Stahler Rachel AChief Information Officer
|
Exercise / conversionCommon Stock | 8,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022424 · wk-form4_1774988203.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,510.292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 16:14 UTC |
Karp DanielExecutive VP, Corp. Dev.
|
Exercise / conversionRestricted Stock Units · Derivative | 14,184 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022415 · wk-form4_1774988059.xml · derivative · entry 3 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,185 Underlying: Common Stock · 14,184 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F4 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. F4 · derivative.expiration_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 16:14 UTC |
Karp DanielExecutive VP, Corp. Dev.
|
Tax withholdingCommon Stock | 4,446 | $5.84 | $25,964.64 |
DisclosureSEC source: 0001628280-26-022415 · wk-form4_1774988059.xml · nonDerivative · entry 2 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,153.923 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 27, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. F2 · balance_after: Includes the addition of 746.463 shares of Organon common stock acquired from dividend equivalents net of withholding tax not previously required to be reported. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 16:14 UTC |
Karp DanielExecutive VP, Corp. Dev.
|
Exercise / conversionCommon Stock | 14,184 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022415 · wk-form4_1774988059.xml · nonDerivative · entry 1 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,853.46 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 20:11 UTC |
Nisita VittorioHead of Global Business Svcs
|
Exercise / conversionRestricted Stock Units · Derivative | 5,762 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022404 · wk-form4_1774987911.xml · derivative · entry 3 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,763 Underlying: Common Stock · 5,762 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F3 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. F3 · derivative.expiration_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 20:11 UTC |
Nisita VittorioHead of Global Business Svcs
|
Tax withholdingCommon Stock | 1,974 | $5.84 | $11,528.16 |
DisclosureSEC source: 0001628280-26-022404 · wk-form4_1774987911.xml · nonDerivative · entry 2 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,072.158 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 27, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 20:11 UTC |
Nisita VittorioHead of Global Business Svcs
|
Exercise / conversionCommon Stock | 5,762 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022404 · wk-form4_1774987911.xml · nonDerivative · entry 1 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,046.158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 20:08 UTC |
Falcione AaronChief Human Resources Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 8,422 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022383 · wk-form4_1774987683.xml · derivative · entry 3 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,422 Underlying: Common Stock · 8,422 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F3 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. F3 · derivative.expiration_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 20:08 UTC |
Falcione AaronChief Human Resources Officer
|
Tax withholdingCommon Stock | 2,885 | $5.84 | $16,848.40 |
DisclosureSEC source: 0001628280-26-022383 · wk-form4_1774987683.xml · nonDerivative · entry 2 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,646.071 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 27, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 20:08 UTC |
Falcione AaronChief Human Resources Officer
|
Exercise / conversionCommon Stock | 8,422 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022383 · wk-form4_1774987683.xml · nonDerivative · entry 1 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,531.071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 20:05 UTC |
Morrissey Joseph T. Jr.Interim CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 9,752 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022368 · wk-form4_1774987546.xml · derivative · entry 3 Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,752 Underlying: Common Stock · 9,752 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F3 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. F3 · derivative.expiration_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 20:05 UTC |
Morrissey Joseph T. Jr.Interim CEO
|
Tax withholdingCommon Stock | 2,779 | $5.84 | $16,229.36 |
DisclosureSEC source: 0001628280-26-022368 · wk-form4_1774987546.xml · nonDerivative · entry 2 Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,543.923 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 27, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 20:05 UTC |
Morrissey Joseph T. Jr.Interim CEO
|
Exercise / conversionCommon Stock | 9,752 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022368 · wk-form4_1774987546.xml · nonDerivative · entry 1 Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,322.923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 18:58 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
Tax withholdingCommon Stock | 1,763 | $7.23 | $12,746.49 |
DisclosureSEC source: 0001628280-26-014222 · wk-form4_1772582299.xml · nonDerivative · entry 4 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,854.163 F3 · balance_after: Includes the addition of 1,832.163 shares of Common Stock acquired from dividend equivalents not previously required to be reported. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 18:58 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
GrantCommon Stock | 6,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014222 · wk-form4_1772582299.xml · nonDerivative · entry 3 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,785 F2 · shares: Represents the shares of Common Stock released to cover the dividend equivalents earned on the PSUs released above. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 18:58 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
Tax withholdingCommon Stock | 6,815 | $7.17 | $48,863.55 |
DisclosureSEC source: 0001628280-26-014222 · wk-form4_1772582299.xml · nonDerivative · entry 2 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,599 Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 18:58 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
GrantCommon Stock | 21,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014222 · wk-form4_1772582299.xml · nonDerivative · entry 1 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,414 F1 · shares: Represents shares of Organon & Co. common stock ("Common Stock") for performance share units ("PSUs") granted to the reporting person on August 11, 2023 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:01 UTC |
WALSH MATTHEW MChief Financial Officer
|
Tax withholdingCommon Stock | 4,117 | $7.23 | $29,765.91 |
DisclosureSEC source: 0001628280-26-014228 · wk-form4_1772582504.xml · nonDerivative · entry 4 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,751 F3 · balance_after: Includes the addition of 652 shares of Common Stock acquired from dividend equivalents net of withholding tax not previously required to be reported. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:01 UTC |
WALSH MATTHEW MChief Financial Officer
|
GrantCommon Stock | 12,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014228 · wk-form4_1772582504.xml · nonDerivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,216 F2 · shares: Represents the shares of Common Stock released to cover the dividend equivalents earned on the PSUs released above. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:01 UTC |
WALSH MATTHEW MChief Financial Officer
|
Tax withholdingCommon Stock | 14,887 | $7.17 | $106,739.79 |
DisclosureSEC source: 0001628280-26-014228 · wk-form4_1772582504.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,196 Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:01 UTC |
WALSH MATTHEW MChief Financial Officer
|
GrantCommon Stock | 42,599 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014228 · wk-form4_1772582504.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,083 F1 · shares: Represents shares of Organon & Co. common stock ("Common Stock") for performance share units ("PSUs") granted to the reporting person on August 11, 2023 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 18:59 UTC |
Stahler Rachel AChief Information Officer
|
Tax withholdingCommon Stock | 2,240 | $7.23 | $16,195.20 |
DisclosureSEC source: 0001628280-26-014224 · wk-form4_1772582358.xml · nonDerivative · entry 4 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,310.292 F3 · balance_after: Includes the addition of 2,076.678 shares of Common Stock acquired from dividend equivalents net of withholding tax not previously required to be reported. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 18:59 UTC |
Stahler Rachel AChief Information Officer
|
GrantCommon Stock | 6,540 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014224 · wk-form4_1772582358.xml · nonDerivative · entry 3 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,473.614 F2 · shares: Represents the shares of Common Stock released to cover the dividend equivalents earned on the PSUs released above. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 18:59 UTC |
Stahler Rachel AChief Information Officer
|
Tax withholdingCommon Stock | 8,475 | $7.17 | $60,765.75 |
DisclosureSEC source: 0001628280-26-014224 · wk-form4_1772582358.xml · nonDerivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,933.614 Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 18:59 UTC |
Stahler Rachel AChief Information Officer
|
GrantCommon Stock | 23,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014224 · wk-form4_1772582358.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,408.614 F1 · shares: Represents shares of Organon & Co. common stock ("Common Stock") for performance share units ("PSUs") granted to the reporting person on August 11, 2023 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:02 UTC |
Falcione AaronChief Human Resources Officer
|
Tax withholdingCommon Stock | 2,301 | $7.23 | $16,636.23 |
DisclosureSEC source: 0001628280-26-014231 · wk-form4_1772582565.xml · nonDerivative · entry 4 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,109.071 F3 · balance_after: Includes the addition of 1,619.41 shares of Common Stock acquired from dividend equivalents net of withholding tax not previously required to be reported. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:02 UTC |
Falcione AaronChief Human Resources Officer
|
GrantCommon Stock | 6,717 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014231 · wk-form4_1772582565.xml · nonDerivative · entry 3 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,790.661 F2 · shares: Represents the shares of Common Stock released to cover the dividend equivalents earned on the PSUs released above. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:02 UTC |
Falcione AaronChief Human Resources Officer
|
Tax withholdingCommon Stock | 8,705 | $7.17 | $62,414.85 |
DisclosureSEC source: 0001628280-26-014231 · wk-form4_1772582565.xml · nonDerivative · entry 2 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,073.661 Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:02 UTC |
Falcione AaronChief Human Resources Officer
|
GrantCommon Stock | 23,805 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014231 · wk-form4_1772582565.xml · nonDerivative · entry 1 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,778.661 F1 · shares: Represents shares of Organon & Co. common stock ("Common Stock") for performance share units ("PSUs") granted to the reporting person on August 11, 2023 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:00 UTC |
Nisita VittorioHead of Global Business Svcs
|
Tax withholdingCommon Stock | 1,575 | $7.23 | $11,387.25 |
DisclosureSEC source: 0001628280-26-014226 · wk-form4_1772582428.xml · nonDerivative · entry 4 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,284.158 F3 · balance_after: Includes the addition of 1,364.619 shares of Common Stock acquired from dividend equivalents net of withholding tax not previously required to be reported. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:00 UTC |
Nisita VittorioHead of Global Business Svcs
|
GrantCommon Stock | 4,596 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014226 · wk-form4_1772582428.xml · nonDerivative · entry 3 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,494.539 F2 · shares: Represents the shares of Common Stock released to cover the dividend equivalents earned on the PSUs released above. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:00 UTC |
Nisita VittorioHead of Global Business Svcs
|
Tax withholdingCommon Stock | 6,210 | $7.17 | $44,525.70 |
DisclosureSEC source: 0001628280-26-014226 · wk-form4_1772582428.xml · nonDerivative · entry 2 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,898.539 Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:00 UTC |
Nisita VittorioHead of Global Business Svcs
|
GrantCommon Stock | 16,287 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014226 · wk-form4_1772582428.xml · nonDerivative · entry 1 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,108.539 F1 · shares: Represents shares of Organon & Co. common stock ("Common Stock") for performance share units ("PSUs") granted to the reporting person on August 11, 2023 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:56 UTC |
Morrissey Joseph T. Jr.Interim CEO
|
Tax withholdingCommon Stock | 2,216 | $7.23 | $16,021.68 |
DisclosureSEC source: 0001628280-26-014211 · wk-form4_1772582201.xml · nonDerivative · entry 4 Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,570.923 F3 · balance_after: Includes the addition of 1,938.068 shares of Common Stock acquired from dividend equivalents net of withholding tax not previously required to be reported. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:56 UTC |
Morrissey Joseph T. Jr.Interim CEO
|
GrantCommon Stock | 7,777 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014211 · wk-form4_1772582201.xml · nonDerivative · entry 3 Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,848.855 F2 · shares: Represents the shares of Common Stock released to cover the dividend equivalents earned on the PSUs released above. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:56 UTC |
Morrissey Joseph T. Jr.Interim CEO
|
Tax withholdingCommon Stock | 8,054 | $7.17 | $57,747.18 |
DisclosureSEC source: 0001628280-26-014211 · wk-form4_1772582201.xml · nonDerivative · entry 2 Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,071.855 Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:56 UTC |
Morrissey Joseph T. Jr.Interim CEO
|
GrantCommon Stock | 27,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014211 · wk-form4_1772582201.xml · nonDerivative · entry 1 Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,125.855 F1 · shares: Represents shares of Organon & Co. common stock ("Common Stock") for performance share units ("PSUs") granted to the reporting person on August 11, 2023 under the Organon & Co. 2023 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 21:05 UTC |
Drinane Juliana PapaInterim Head of Mfg & Supply
|
GrantRestricted Stock Units · Derivative | 65,616 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-052592 · wk-form4_1763413497.xml · derivative · entry 1 Drinane Juliana Papa · CIK 0002096406 · Interim Head of Mfg & Supply 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,616 Underlying: Common Stock · 65,616 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") converts into one share of Organon & Co. common stock. F2 · derivative.exercise_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On November 13, 2025, RSUs were granted and will vest in three equal installments on each of November 13, 2026, November 13, 2027, and November 13, 2028. F2 · derivative.expiration_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On November 13, 2025, RSUs were granted and will vest in three equal installments on each of November 13, 2026, November 13, 2027, and November 13, 2028. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 21:04 UTC |
Morrissey Joseph T. Jr.Interim CEO
|
GrantRestricted Stock Units · Derivative | 131,233 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-052590 · wk-form4_1763413454.xml · derivative · entry 1 Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,233 Underlying: Common Stock · 131,233 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: The Reporting Person was granted RSUs on November 13, 2025 (which was the close of business on the third business day following the release of Organon's earnings for the quarter ended September 30, 2025, on November 10, 2025). These RSUs vest and become exercisable in three equal installments on November 13, 2026, November 13, 2027, and November 13, 2028. F2 · derivative.expiration_date: The Reporting Person was granted RSUs on November 13, 2025 (which was the close of business on the third business day following the release of Organon's earnings for the quarter ended September 30, 2025, on November 10, 2025). These RSUs vest and become exercisable in three equal installments on November 13, 2026, November 13, 2027, and November 13, 2028. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 21:05 UTC |
COX CARRIE SMITHDirector · Executive Chair
|
PurchaseCommon Stock | 65,400 | $7.67 | $501,755.34 |
DisclosureSEC source: 0001628280-25-052004 · wk-form4_1763067905.xml · nonDerivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director · Executive Chair 10b5-1 filing: No plan indicated Ownership: Indirect · IRA Disclosed balance after: 77,869 F1 · price: The price reported is a weighted average price of $7.6721. These shares were purchased in multiple transactions at prices ranging from $7.6630 to $7.6899, inclusive. The reporting person undertakes to provide to Organon & Co. ("Organon"), any security holder of Organon, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 21:04 UTC |
Holzbaur LynetteSVP and Corporate Controller
|
Exercise / conversionRestricted Stock Units · Derivative | 2,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-051009 · wk-form4_1762808694.xml · derivative · entry 3 Holzbaur Lynette · CIK 0002068746 · SVP and Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,418 Underlying: Common Stock · 2,417 shares Expires 2026-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. common stock. F2 · derivative.exercise_date: 7,252 RSUs were granted 11/7/2023, and one-third vest each year with the final vesting date being 11/7/2026. Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 21:04 UTC |
Holzbaur LynetteSVP and Corporate Controller
|
Tax withholdingCommon Stock | 689 | $6.71 | $4,623.19 |
DisclosureSEC source: 0001628280-25-051009 · wk-form4_1762808694.xml · nonDerivative · entry 2 Holzbaur Lynette · CIK 0002068746 · SVP and Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,676.427 Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 21:04 UTC |
Holzbaur LynetteSVP and Corporate Controller
|
Exercise / conversionCommon Stock | 2,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-051009 · wk-form4_1762808694.xml · nonDerivative · entry 1 Holzbaur Lynette · CIK 0002068746 · SVP and Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,365.427 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 21:14 UTC |
Arjona Ferreira Juan CamiloHead of R&D & CMO
|
Exercise / conversionRestricted Stock Units · Derivative | 6,446 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-051052 · wk-form4_1762809245.xml · derivative · entry 3 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,447 Underlying: Common Stock · 6,446 shares Expires 2026-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three installments: 6,446 shares on November 7 2024; 6,446 shares on November 7, 2025; and 6,447 shares on November 7, 2026. Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 21:14 UTC |
Arjona Ferreira Juan CamiloHead of R&D & CMO
|
Tax withholdingCommon Stock | 2,307 | $6.71 | $15,479.97 |
DisclosureSEC source: 0001628280-25-051052 · wk-form4_1762809245.xml · nonDerivative · entry 2 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,916.355 Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 21:14 UTC |
Arjona Ferreira Juan CamiloHead of R&D & CMO
|
Exercise / conversionCommon Stock | 6,446 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-051052 · wk-form4_1762809245.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,223.355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 22:48 UTC |
Drinane Juliana PapaInterim Head of Mfg & Supply
|
Exercise / conversionRestricted Stock Units · Derivative | 3,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-051733 · wk-form4_1762987721.xml · derivative · entry 3 Drinane Juliana Papa · CIK 0002096406 · Interim Head of Mfg & Supply 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,626 Underlying: Common Stock · 3,626 shares Expires 2026-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Organon & Co. F2 · derivative.exercise_date: 10,876 restricted stock units ("RSUs") were granted on November 7, 2023, and one-third vest each year with the final vesting date being November 7, 2026. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 22:48 UTC |
Drinane Juliana PapaInterim Head of Mfg & Supply
|
Tax withholdingCommon Stock | 1,242 | $6.71 | $8,333.82 |
DisclosureSEC source: 0001628280-25-051733 · wk-form4_1762987721.xml · nonDerivative · entry 2 Drinane Juliana Papa · CIK 0002096406 · Interim Head of Mfg & Supply 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,658.703 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.